Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

NCT02196857 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: Azacytidine
DRUG: Sorafenib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]